TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER

摘要

An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves de-livering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.